-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taletrectinib Adipate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taletrectinib Adipate in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taletrectinib Adipate in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Safusidenib in Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Safusidenib in Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Safusidenib in Glioma Drug Details: DS-1001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Safusidenib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Safusidenib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Safusidenib in Solid Tumor Drug Details: DS-1001 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Safusidenib in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Safusidenib in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Safusidenib in Low-Grade Glioma Drug Details: DS-1001 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Safusidenib in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Safusidenib in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Safusidenib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: DS-1001 is...
-
Product Insights
Low-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Low-Grade Glioma - Drugs In Development, 2023’, provides an overview of the Low-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Low-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Plogosertib is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Albicin in Warts
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Albicin in Warts Drug Details: Albicin is under development for the treatment of warts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orvacabtagene Autoleucel in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orvacabtagene Autoleucel in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Orvacabtagene Autoleucel in Relapsed Multiple Myeloma Drug Details:Orvacabtagene autoleucel (ET-140) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taletrectinib Adipate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taletrectinib Adipate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taletrectinib Adipate in Solid Tumor Drug Details: Taletrectinib (DS-6051b/AB-106) is under...